Inhibrx's Multivalent Biologics Face Major Clinical Tests Post-Sanofi

SAN DIEGO, Oct. 13, 2026 — For biopharmaceutical companies that survive a major corporate restructuring, the subsequent clinical readouts are more than just data points—they are referendums on the surviving scientific platform. Inhibrx Biosciences, Inc. (Nasdaq: INBX) is about to face exactly that kind of scrutiny. The clinical-stage company announced today that it will present critical data from its two lead oncology programs across three major scientific conferences this fall: the European Society for Medical Oncology (ESMO) Congress, the Musculoskeletal Tumor Society (MSTS) Annual Meeting, and the Connective Tissue Oncology Society (CTOS) Annual Meeting.

The flurry of upcoming presentations marks a defining season for Inhibrx. Following the high-profile sale of its predecessor company and the INBRX-101 program to Sanofi S.A. in early 2024, the newly spun-out Inhibrx Biosciences retained the company's proprietary protein engineering platforms and a pipeline of multivalent oncology candidates. Now, the biotech industry is watching closely to see if the company's engineered biologic therapeutics—specifically its tetravalent and hexavalent agonists—can deliver on their clinical promise.

Post-Sanofi Rebirth: Proving the Multivalent Platform

When Sanofi acquired the original Inhibrx, Inc., the pharmaceutical giant was primarily interested in INBRX-101, an optimized recombinant human alpha-1 antitrypsin for treating alpha-1 antitrypsin deficiency. The remaining assets, corporate infrastructure, and liabilities were spun out into Inhibrx Biosciences, with 92% of the new entity's shares distributed to existing stockholders.

This "Inhibrx 2.0" was left with a clear but challenging mandate: prove that its diverse methods of protein engineering can successfully address the complex requirements of targeted disease biology. The company's core hypothesis centers on valency—the number of antigen-binding sites on an antibody. By utilizing multivalent formats (tetravalent and hexavalent), Inhibrx believes it can optimize receptor clustering in a target-centric way, mediating more appropriate and potent agonist functions than traditional bivalent antibodies.

The upcoming data readouts at ESMO, MSTS, and CTOS will serve as the definitive proof-of-concept for this retained pipeline. With the company operating independently, these clinical updates are not only scientific milestones but also critical catalysts for the company's valuation, future partnership opportunities, and long-term cash runway.

Chondrosarcoma Breakthrough: Cracking an Untreatable Sarcoma

The most mature asset in Inhibrx's portfolio is ozekibart (INBRX-109), a precision-engineered, tetravalent death receptor 5 (DR5) agonist. At the MSTS Annual Meeting in Miami on October 29, lead author Robin Jones will deliver an oral presentation detailing secondary efficacy endpoints from the Phase 2 ChonDRAgon study in conventional chondrosarcoma. Weeks later, on November 20 at the CTOS Annual Meeting in Seoul, Sant Chawla will present subgroup analyses and updated progression-free survival (PFS) data from the same trial.

Conventional chondrosarcoma is a rare, malignant bone tumor notorious for its resistance to standard chemotherapy and radiation. Currently, there are no approved systemic therapies for patients with unresectable or metastatic disease. Ozekibart aims to change this by exploiting DR5, a receptor highly expressed on tumorigenic cells. The drug's tetravalent structure is designed to cluster DR5 receptors effectively, triggering tumor-biased apoptosis (programmed cell death) while sparing healthy tissue.

The ChonDRAgon study (NCT04950075) is the largest randomized trial ever conducted in this indication, enrolling 206 patients. In late 2025, Inhibrx reported that the trial met its primary endpoint, more than doubling median PFS to 5.52 months compared to 2.66 months for placebo—a 52% reduction in the risk of disease progression or death.

Industry observers note that the upcoming MSTS and CTOS presentations are critical for cementing the drug's efficacy profile. The U.S. Food and Drug Administration (FDA) has already accepted a Biologics License Application (BLA) for ozekibart, setting a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027. If the updated PFS data and secondary endpoints—such as disease control rate and pain deterioration delays—hold strong, ozekibart is well-positioned to become the first approved systemic therapy for this devastating disease.

Taming the Immune Agonist: Hexavalent OX40 in Head and Neck Cancer

While ozekibart advances toward potential commercialization, Inhibrx is simultaneously pushing the boundaries of immuno-oncology with ordastobart (INBRX-106). On October 25, at the ESMO Congress in Madrid, lead author Jong Chul Park will present the Phase 2 primary analysis of the HexAgon-HN study. This trial evaluates ordastobart in combination with pembrolizumab (Keytruda) as a first-line treatment for PD-L1-high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Ordastobart is a hexavalent OX40 agonist. OX40 is a co-stimulatory receptor expressed on activated T cells, making it a tantalizing target for cancer immunotherapy. However, the clinical history of OX40 agonists is littered with failures. Earlier generation bivalent antibodies often failed to induce sufficient receptor clustering, resulting in lackluster clinical efficacy or, conversely, unmanageable systemic toxicity due to overactivation of the immune system.

Inhibrx's hexavalent architecture is engineered to overcome these historical hurdles by forcing a higher degree of receptor cross-linking, which preclinical models suggest is necessary for robust OX40 signaling. By combining ordastobart with pembrolizumab—the current standard of care that removes the "brakes" from the immune system via PD-1 blockade—Inhibrx hopes to create a synergistic effect that drives deep and durable anti-tumor responses.

Oncology researchers and pharmaceutical industry analysts will be scrutinizing the ESMO presentation to see if ordastobart can finally unlock the potential of the OX40 pathway without triggering unacceptable adverse events. Success here would not only validate ordastobart but also heavily endorse Inhibrx's hexavalent engineering platform as a tool for rescuing historically "undruggable" or problematic immune targets.

Expanding the Pipeline: Combination Strategies in Ewing Sarcoma

Rounding out the company's conference circuit is a poster presentation at CTOS on November 19 by lead author Varun Monga. This presentation will cover a Phase 1/2 study evaluating ozekibart in a completely different setting: combined with the chemotherapies irinotecan and temozolomide in adolescents and adults with Ewing sarcoma.

The biological rationale for this combination is compelling. Irinotecan and temozolomide are cytotoxic agents that induce DNA damage, which can trigger cellular stress responses and potentially sensitize cancer cells to DR5-mediated apoptosis. By adding ozekibart to the mix, investigators hope to significantly amplify the tumor cell death rate.

Historically, the irinotecan and temozolomide (IT) regimen has yielded modest objective response rates of 10% to 30% in relapsed or refractory Ewing sarcoma, a notoriously aggressive pediatric and young adult bone cancer. If the addition of Inhibrx's tetravalent DR5 agonist can meaningfully improve upon these historical benchmarks without compounding toxicity, it could open a vital new therapeutic avenue for a patient population in desperate need of innovation.

As Inhibrx Biosciences prepares to take the stage in Madrid, Miami, and Seoul, the stakes are undeniably high. The data unveiled in the coming weeks will do more than just update clinical trial records; it will dictate the strategic and financial trajectory of the company as it seeks to transition from a clinical-stage biotech into a commercial-stage oncology leader.